In Schedule 11 to the principal Regulations (drugs to be supplied by general medical practitioners or prescribed for supply under pharmaceutical services only in certain circumstances) after the entry relating to Nizoral Cream there is inserted in columns 1, 2 and 3 respectively the following–
The following drugs for the treatment of erectile dysfunction–
Alprostadil (Caverject), (MUSE), (Viridal)
Moxisylyte Hydrochloride (Erecnos)
Thymoxamine Hydrochloride (Erecnos)
Sildenafil (Viagra)
(a) A man with erectile dysfunction
who on 14th September 1998 was receiving treatment
under the Act for this condition with any of the following drugs–
Alprostadil (Caverject), (MUSE), (Viridal)
Moxisylyte Hydrochloride (Erecnos)
Thymoxamine Hydrochloride (Erecnos)
Sildenafil (Viagra); or
(b) a man who is suffering from any of the following–
diabetes
multiple sclerosis
Parkinson’s disease
poliomyelitis
prostate cancer
severe pelvic injury
single gene neurological disease
spina bifida
spinal cord injury; or
(c) a man who is receiving treatment for renal failure by dialysis; or
(d) a man who has had the following surgery–
prostatectomy
radical pelvic surgery
renal failure treated by transplant